Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of Immunohistochemistry Technique in Detecting Her2 Overexpression in Invasive Ductal Breast Carcinoma Using Fluorescence In-Situ Hybridization Method



Baradaran A1 ; Hajalikhani P2 ; Gheybi MK3 ; Mohajeri MR4 ; Mehrabikoushki A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. School of Medicine, Boushehr University of Medical Sciences, Boushehr, Iran
  4. 4. Pathologist, Isfahan, Iran
  5. 5. Department of Epidemiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2016

Abstract

Background: Breast cancer is the most common cancer among women. HER2 gene is a proto-oncogene that encodes the receptor of tyrosine kinase from epidermal growth factor receptor (EFGR) family. It is an important prognostic factor with a determinant role in treatment of breast cancer. There is no globally accepted method for determining the status of this gene and the method of choice is still a matter of debate. We aimed to evaluate the validity of immunohistochemistry (IHC) method in predicting HER2 status using fluorescence in-situ hybridization (FISH) method and also, to investigate some clinicopathological variables associated with HER2 amplification. Methods: In this cross-sectional study, 190 formalin-fixed and paraffin-embedded tissue specimens of invasive breast carcinoma with HER2 of ++ and +++ in IHC evaluation were enrolled. FISH method was performed on all these samples and the relationship of HER2 status and clinicopathological variables was evaluated. Findings: The studied population included 160 specimens of ++ and 30 specimens of +++ HER2 in IHC evaluation. The estrogen and progesterone receptors (ER and PR) were expressed in 64.2% and 74.2% of the specimens, respectively. HER2 amplification on FISH method was found in 27.5% and 83.3% of specimens of ++ and +++ HER2 in IHC evaluation, respectively. Tumors with HER2 amplification were more likely to be negative for estrogen (52.2% vs. 26.4%, P < 0.001) and progesterone (39.1% vs. 18.2 %, P = 0.013) receptors. Conclusion: This study showed that immunohistochemistry is not a good method for evaluating HER2 status and decision making about trastuzumab therapy even in patients with +++ HER2. © 2016, Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Validity of Immunohistochemistry Method in Predicting Her-2 Gene Status and Association of Clinicopathological Variables With It in Invasive Breast Cancer Patients, APMIS (2016)
2. Linear and Conformational B Cell Epitope Prediction of the Her 2 Ecd-Subdomain Iii by in Silico Methods, Asian Pacific Journal of Cancer Prevention (2012)
3. Multicentricity in Different Molecular Subtypes of Breast Cancer: A Cross-Sectional Study in Isfahan, Advanced Biomedical Research (2023)
4. Discordance of Human Epidermal Growth Factor Receptor-2 Expression in Primary Breast Cancer and Related Axillary Lymph Node Metastasis, Asian Journal of Pharmaceutics (2018)
5. The Prognostic Significance of Her2-Neu Over Expression in Gastric Carcinomas, Iranian Journal of Cancer Prevention (2011)
6. Improved Biological Activity of a Single Chain Antibody Fragment Against Human Epidermal Growth Factor Receptor 2 (Her2) Expressed in the Periplasm of Escherichia Coli, Protein Expression and Purification (2015)
7. Association Between Radio-Pathological Breast Tumor Characteristics and Mammographic Breast Density, Archives of Breast Cancer (2024)
8. Mir-195 Down-Regulation Is a Distinctive Biomarker of Her2 Positive State in Breast Cancer, Gene Reports (2020)
Experts (# of related papers)
View all Related Experts
Abbas Jafarian (5)
Azar Naimi (4)
Other Related Docs
9. Comparing Efficacy and Safety of P013, a Proposed Pertuzumab Biosimilar, With the Reference Product in Her2-Positive Breast Cancer Patients: A Randomized, Phase Iii, Equivalency Clinical Trial, BMC Cancer (2022)
10. Design and Construction of Scfv-Pe35kdel As a Novel Immunotoxin Against Human Epidermal Growth Factor Receptor 2 for Cancer Therapy, Biotechnology Letters (2023)
11. Ephb4 Tyrosine Kinase Stimulation Inhibits Growth of Mda-Mb-231 Breast Cancer Cells in a Dose and Time Dependent Manner, Disease Markers (2013)
12. In Silico Design of Discontinuous Peptides Representative of B and T-Cell Epitopes From Her2-Ecd As Potential Novel Cancer Peptide Vaccines, Asian Pacific Journal of Cancer Prevention (2013)
13. Deep Radiogenomics Sequencing for Breast Tumor Gene-Phenotype Decoding Using Dynamic Contrast Magnetic Resonance Imaging, Molecular Imaging and Biology (2025)
14. Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in Situ and Invasive Components in Breast Carcinoma, Iranian Journal of Pathology (2024)
15. Expression of Basal and Luminal Cytokeratins in Breast Cancer and Their Correlation With Clinicopathological Prognostic Variables, Indian Journal of Medical Sciences (2009)
16. Investigation of Her-2 Expression and Its Correlation With Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients, Iranian Journal of Pathology (2020)
17. Functional Expression of a Single-Chain Antibody Fragment Against Human Epidermal Growth Factor Receptor 2 (Her2) in Escherichia Coli, Journal of Industrial Microbiology and Biotechnology (2014)
18. Role of Cyclin D1 in Breast Carcinoma, Journal of Research in Medical Sciences (2013)
19. Therapeutic Potential of Plk1, Kif4a, Cdca5, Ube2c, Cdt1, Ska3, Aurkb, and Pttg1 Genes in Triple-Negative Breast Cancer: Correlating Their Expression With Sensitivity to Gsk 461364 and Ikk 16 Drugs, Biochemical Genetics (2024)
20. A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe, Analytical Methods (2019)
21. Investigation of Prognostic Factors in Breast Cancer and Their Relationship With Age and Cancer Stage, Journal of Isfahan Medical School (2012)
22. Association of Mammographic and Sonographic Findings With Prognostic Molecular Factors and Hormone Receptor Expression in Malignant Breast Lesions, Journal of Research in Medical Sciences (2024)
23. Association of the Length of Ca Dinucleotide Repeat in the Epidermal Growth Factor Receptor With Risk and Age of Breast Cancer Onset in Isfahan, Journal of Isfahan Medical School (2008)
24. Production and Characterization of New Anti-Her2 Monoclonal Antibodies, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2015)
25. St6gal1, Cox-2 and Hb-Egf Mrna Expression in Breast Cancer Samples From Kashan, Iran, Middle East Journal of Cancer (2015)